Patents
Literature
17 results about "Viral Oncogene" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cancer-causing genes encoded in viral genomes. Usually denoted v-onc.
Heterobifunctional compounds for the degradation of KRAS protein
PCT designated stage expiredWO2025006753A2Organic active ingredientsOrganic chemistryViral OncogeneRat sarcoma virus
Owner:MERCK PATENT GMBH +2
Heterobifunctional compounds for the degradation of kras
PCT designated stage expiredWO2025006783A2Organic active ingredientsOrganic chemistryViral OncogeneRat sarcoma virus
Owner:ANDERSON COREY DON +3
Pharmaceutical composition containing PRMT5 inhibitor and kras g12c inhibitor
PCT designated stageWO2025157289A1Antineoplastic agentsPharmaceutical active ingredientsViral OncogeneDisease
A pharmaceutical composition comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and a KRASG12C (Kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine) inhibitor. The pharmaceutical composition can be used for treating various cancers, comprising solid tumors. The combined product can be used for treating any number of diseases associated with PRMT5 and / or KRASG12C.
Owner:SHANGHAI APEIRON THERAPEUTICS CO LTD
Novel compounds as KRAS inhibitors and uses thereof
Described herein are Kirsten rat sarcoma viral oncogene homologue (KRAS) inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a KRAS associated disease or disorder.
Owner:INSILICO MEDICINE IP LTD
Anti-mutated KRAS t cell receptors
Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
HLA class II-restricted t cell receptors against mutated RAS
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Neoantigen peptide mimics
ActiveUS12275766B2Tumor rejection antigen precursorsPeptide/protein ingredientsViral OncogeneAntigen
Disclosed herein are polypeptide fragments and polynucleotides based on mutant capicua transcriptional repressor (CIC), catenin beta 1 (CTNNB1), v-erb-b2 erythroblastic leukemia viral oncogene homolog B (ERBB2), kirsten rat sarcoma (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN), splicing factor 3b subunit 1 (SF3B1), SRY-box transcription factor 17 (SOX17), tumor protein 53 (TP53), and cytomegalovirus (CMV) sequences, vectors, host cells, viruses, methods for generating CD8+ T-cells, and methods of treatment. Also disclosed herein are T-cell receptors (TCRs), polynucleotides, vectors and cells comprising the TCRs, and methods of treatment.
Owner:JANSSEN BIOTECH INC
Methods of using Anti-EGF antibodies to augment the activity of BRAF and KRAS inhibitors
Embodiments of the present disclosure are directed to methods for treating and preventing disease conditions, such as cancer, particularly in those individuals who have developed a resistance to, or who are not responsive to, cancer therapies involving v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) or Kirsten rat sarcoma oncogene homolog (KRAS) inhibitors.
Owner:IN3BIO LTD
T cell receptors recognizing HLA-CW8 restricted mutated KRAS
Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Anti-KRAS-G12D T cell receptors
Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Anti-KRAS-g12d t cell receptors
Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
Compositions for modulating the KRAS pathway and methods of use thereof
PCT designated stage expiredWO2025076318A1Microbiological testing/measurementAntibody ingredientsViral OncogeneDisease
The present invention relates to methods for diagnosing and treating diseases associated with an increased level of Kirsten rat sarcoma viral oncogene homologue (KRAS) signaling or secreted frizzled-related protein 2 (SFRP2), as well as, compositions and methods for modulating KRAS signaling or SFRP2 for the treatment of diseases or disorders such as cancer.
Owner:MUSC FOUNDATION FOR RESEARCH DEVELOPMENT(US)
Heterobifunctional compounds for the degradation of kras
PCT designated stage expiredWO2025006783A3Viral OncogeneRat sarcoma virus
Owner:ANDERSON COREY DON +3
Anti-mutated KRAS T cell receptors
Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
HLA class ii-restricted t cell receptors against mutated ras
PendingUS20250250318A1Immunoglobulin superfamilyPeptide/protein ingredientsViral OncogeneHla class ii
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES